Instil Bio, Inc. (TIL): Total Liabilities
$89.66M
As of 2025-12-31
$90.33M
As of 2026-06-30
-8.9%
3-year compound annual growth
+27.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $89.66M | -4.8% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $94.13M | -5.7% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $99.80M | -15.8% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $118.52M | +116.3% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $54.78M | +105.6% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $26.64M | n/a | 2022-03-07, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | 2025-12-31 | $89.66M | -4.8% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $13.06M | -8.8% |
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $87.18M | +191.5% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $22.80M | +50.3% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $62.51M | -30.3% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $53.76M | +39.4% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $159.25M | -23.2% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $64.77M | -66.2% |
Compare TIL, TARA, NMRA, CMPX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗